Pancreatic Cancer Research

ResearcherGerman Cancer Research CenterActive in the last 2 years

Lena Seifert

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0003-4763-8127; OpenAlex author ID A5037852116. Sources: OpenAlex.

Their work

Papers
20 (first author 1, last author 9)
Trials
0
Grants
0
Labs led
1
Collaborators
38
Papers, trials and grants by year

2020: 3 papers · 2021: 1 paper · 2022: 2 papers · 2023: 5 papers · 2024: none · 2025: 3 papers · 2026: 6 papers

Papers 20

  1. The rationale for targeting nectin-4 in pancreatic cancer. First author DOI 10.1016/j.trecan.2026.01.008↗
  2. A pancreatic cancer organoid-macrophage co-culture using starPEG-heparin hydrogel deciphers tumor-immune cell interactions. Co-author DOI 10.1038/s41698-026-01678-6↗
  3. Nectin-4 reduces T cell effector function and is a therapeutic target in pancreatic cancer. Co-author DOI 10.1172/jci.insight.194290↗
  4. Combined Preoperative Risk Score Including sCD40, Leukocytes, and BMI Predicts Pancreas-Specific Complications After Pancreatic Cancer Surgery. Last author DOI 10.1245/s10434-026-19628-8↗
  5. ASO Visual Abstract: Combined Preoperative Risk Score Including sCD40, Leukocytes, and BMI Predicts Pancreas-Specific Complications After Pancreatic Cancer Sur… Last author DOI 10.1245/s10434-026-19708-9↗
  6. ASO Author Reflections: sCD40 as a Preoperative Predictor in Pancreatic Cancer Surgery. Last author DOI 10.1245/s10434-026-19716-9↗
  7. Extracellular vesicles from pancreatic cancer and its tumour microenvironment promote increased Schwann cell migration. Co-author DOI 10.1038/s41416-024-02915-0↗
  8. The Value of Blood T Cell Frequencies for Risk Prediction of Postoperative Complications in Pancreatic Cancer Surgery. Last author DOI 10.1097/as9.0000000000000545↗
  9. Predicting resectability after neoadjuvant chemotherapy for patients with borderline resectable pancreatic cancer: a single center, retrospective trial. Co-author DOI 10.3389/fonc.2025.1602933↗
  10. [Familial pancreatic cancer syndrome]. Co-author DOI 10.1007/s00104-023-01819-8↗
  11. Serum immune checkpoint profiling identifies soluble CD40 as a biomarker for pancreatic cancer. Co-author DOI 10.1038/s41698-023-00459-9↗
  12. TIGIT Expression Delineates T-cell Populations with Distinct Functional and Prognostic Impact in Pancreatic Cancer. Last author DOI 10.1158/1078-0432.ccr-23-0258↗
  13. Plasma extracellular vesicle messenger RNA profiling identifies prognostic EV signature for non-invasive risk stratification for survival prediction of patient… Co-author DOI 10.1186/s13045-023-01404-w↗
  14. VISTA Ligation Reduces Antitumor T-Cell Activity in Pancreatic Cancer. Last author DOI 10.3390/cancers15082326↗
  15. Neoadjuvant chemotherapy drives intratumoral T cells toward a proinflammatory profile in pancreatic cancer. Co-author DOI 10.1172/jci.insight.152761↗
  16. Clinical Significance of Tumor-Infiltrating Conventional and Plasmacytoid Dendritic Cells in Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.3390/cancers14051216↗
  17. LAG-3-Expressing Tumor-Infiltrating T Cells Are Associated with Reduced Disease-Free Survival in Pancreatic Cancer. Co-author DOI 10.3390/cancers13061297↗
  18. Gamma-delta T cells stimulate IL-6 production by pancreatic stellate cells in pancreatic ductal adenocarcinoma. Last author DOI 10.1007/s00432-020-03367-8↗
  19. Detection of pancreatic ductal adenocarcinoma with galectin-9 serum levels. Last author DOI 10.1038/s41388-020-1186-7↗
  20. PD-1 Expression by Lymph Node and Intratumoral Regulatory T Cells Is Associated with Lymph Node Metastasis in Pancreatic Cancer. Last author DOI 10.3390/cancers12102756↗

Closest collaborators

The 25 strongest of 38 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Adrian M. Seifert · 18 shared papers, 2020–2026 · strength 3.65
  2. Jürgen Weitz · 18 shared papers, 2020–2026 · strength 3.28
  3. Max Heiduk · 12 shared papers, 2020–2026 · strength 1.81
  4. David Digomann · 9 shared papers, 2021–2026 · strength 1.70
  5. Loreen Natusch Bufe · 5 shared papers, 2025–2026 · strength 1.46
  6. Sarah Cronjaeger · 4 shared papers, 2026 · strength 1.24
  7. Marius Distler · 6 shared papers, 2020–2025 · strength 1.02
  8. Sebastian Hempel · 4 shared papers, 2025–2026 · strength 0.95
  9. Florian Oehme · 4 shared papers, 2025–2026 · strength 0.95
  10. Marc Schmitz · 6 shared papers, 2020–2026 · strength 0.84
  11. Christoph Kahlert · 5 shared papers, 2020–2025 · strength 0.70
  12. Michael B. Ghadimi · 3 shared papers, 2023–2026 · strength 0.66
  13. Ioana Plesca · 4 shared papers, 2021–2023 · strength 0.54
  14. Mathieu Pecqueux · 3 shared papers, 2023–2026 · strength 0.52
  15. Franziska Baenke · 2 shared papers, 2026 · strength 0.45
  16. Daniel E. Stange · 2 shared papers, 2026 · strength 0.45
  17. Fang Cheng Wong · 2 shared papers, 2023–2025 · strength 0.31
  18. Yi Han · 2 shared papers, 2023–2025 · strength 0.31
  19. Thilo Welsch · 3 shared papers, 2020 · strength 0.30
  20. Diane M. Simeone · 1 shared paper, 2026 · strength 0.24
  21. Florian Schepp · 1 shared paper, 2025 · strength 0.24
  22. Christian Teske · 1 shared paper, 2025 · strength 0.24
  23. Julius Thyen · 1 shared paper, 2026 · strength 0.21
  24. Daniela Loessner · 1 shared paper, 2026 · strength 0.21
  25. Verena Kast · 1 shared paper, 2026 · strength 0.21

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.